NCT04386876View on ClinicalTrials.gov

Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

May 22, 2020

Study Completion Date

June 11, 2020

Conditions
Bioequivalence
Interventions
DRUG

Lopinavir/Ritonavir 200 mg/50 mg Film Tablet

Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).

DRUG

Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet

Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)

Trial Locations (2)

27000

Farmagen Ar-Ge Biyot. Ltd. Sti., Şahinbey

06970

Novagenix Drug R&D Center, Akyurt

All Listed Sponsors
collaborator

Novagenix Bioanalytical Drug R&D Center

NETWORK

collaborator

Farmagen Ar-Ge Biyot. Ltd. Sti

NETWORK

lead

World Medicine ILAC SAN. ve TIC. A.S.

INDUSTRY

NCT04386876 - Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions | Biotech Hunter | Biotech Hunter